NCT03966456

Real World Study of Four PD-1 Agents in China

Real World Study of Immunotherapy-Comparison of Four PD-1 Agents in China

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: The Affiliated Hospital of Qingdao University · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.

Detailed description

Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied. ORR will be studied of the four PD-1 agents（nivolumab, pembrolizumab, toripalimab, sintilimab）

Conditions

• Thoracic Cancer
• Gynecologic Cancer
• Abdomen Tumors
• Malignant Melanoma

Interventions

Type	Name	Description
DRUG	Chemotherapy	compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.

Timeline

• Start date: 2018-06-01
• Primary completion: 2021-06-01
• Completion: 2023-06-01
• First posted: 2019-05-29
• Last updated: 2019-05-29

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study